Eisai Co Ltd – Lobbying Governance & Transparency

Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:

Lobbying Governance

Overall Assessment	Analysis	Score
Moderate	Eisai discloses a concrete, though limited, mechanism for keeping its climate-related advocacy in step with its own strategy by focusing on its membership of the Japan Pharmaceutical Manufacturers Association (JPMA). It explains that "Through the progress report from JPMA, Eisai Co., Ltd. is able to confirm if JPMA's initiatives are consistent with Eisai’s climate change measurement strategy," and that once that information is received "they review and share it at the Company-Wide Environment and Safety Committee. The committee members discuss Eisai’s strategy based on the information, and amend it when needed." This indicates that a defined internal body—the Company-Wide Environment and Safety Committee—reviews and can adjust company strategy in response to trade-association positions, suggesting an active governance loop for indirect lobbying. The company also states it has "a public commitment … to conduct [its] engagement activities in line with the goals of the Paris Agreement," reinforcing the intention to align policy engagement with climate goals. However, the disclosure centres solely on JPMA and does not describe how Eisai oversees its own direct lobbying or other industry associations, nor does it identify board-level oversight, a recurring formal audit, or criteria for assessing alignment beyond receiving JPMA progress reports. We found no evidence of a systematic review covering all lobbying channels or of corrective actions such as engaging or exiting misaligned associations. Overall, the information points to a moderate governance approach that covers indirect lobbying through JPMA with committee oversight, but lacks the breadth and depth of a more comprehensive climate-lobbying governance framework. View Sources	C

Overall Assessment

Analysis

Score

Moderate

Eisai discloses a concrete, though limited, mechanism for keeping its climate-related advocacy in step with its own strategy by focusing on its membership of the Japan Pharmaceutical Manufacturers Association (JPMA). It explains that "Through the progress report from JPMA, Eisai Co., Ltd. is able to confirm if JPMA's initiatives are consistent with Eisai’s climate change measurement strategy," and that once that information is received "they review and share it at the Company-Wide Environment and Safety Committee. The committee members discuss Eisai’s strategy based on the information, and amend it when needed." This indicates that a defined internal body—the Company-Wide Environment and Safety Committee—reviews and can adjust company strategy in response to trade-association positions, suggesting an active governance loop for indirect lobbying. The company also states it has "a public commitment … to conduct [its] engagement activities in line with the goals of the Paris Agreement," reinforcing the intention to align policy engagement with climate goals. However, the disclosure centres solely on JPMA and does not describe how Eisai oversees its own direct lobbying or other industry associations, nor does it identify board-level oversight, a recurring formal audit, or criteria for assessing alignment beyond receiving JPMA progress reports. We found no evidence of a systematic review covering all lobbying channels or of corrective actions such as engaging or exiting misaligned associations. Overall, the information points to a moderate governance approach that covers indirect lobbying through JPMA with committee oversight, but lacks the breadth and depth of a more comprehensive climate-lobbying governance framework.

View Sources

Lobbying Transparency

Overall Assessment	Analysis	Score
None	No evidence found	E